Appropriate Screening for Leishmaniasis before Immunosuppressive Treatments | CDC EID

EID Journal Home > Volume 15, Number 10–October 2009

Volume 15, Number 10–October 2009
Letter
Appropriate Screening for Leishmaniasis before Immunosuppressive Treatments
To the Editor: We read with great interest the article by Xynos et al. reporting 2 cases of leishmaniasis in patients treated with biologic drugs (1). Although we agree with most of the article, we are not totally convinced that serologic analysis alone could be used to screen for leishmaniasis before initiation of biologic or immunosuppressive treatments. Evidence indicates that serologic analysis can identify only symptomatic or asymptomatic cases with recent and still active infection (2,3).

Leishmania spp. are pathogens that infect hematopoietic cells, where they establish chronic intracellular parasitism and survive for an infected person's lifetime. In leishmaniasis-endemic countries, asymptomatic visceral leishmaniasis (VL) infections occur more frequently than clinically apparent VL cases. An estimated 10%–20% of persons with asymptomatic infections develop clinically overt VL (4). The leishmanin skin test (LST) (Montenegro test), an intradermal injection of a suspension of killed promastigotes, measures delayed hypersensitivity reactions and appears to be the only screening test capable of detecting asymptomatic leishmania infections.

A positive LST result is thought to indicate durable cell-mediated immunity after asymptomatic infection or clinical cure of VL. LST positivity may appear months to years postinfection, but once positivity appears, it persists in immunocompetent patients. A survey of VL in Ethiopia showed LST positivity in 32.2% of the population, but leishmania antibodies were found in only 4.1% (5).

Because different antigen preparations may affect test sensitivity, LST should use promastigotes of the Leishmania spp. present in an area. We believe that ideal screening for leishmaniasis should include LST along with serologic analysis. Unfortunately, little data exist on the use of antileishmania therapies for LST-positive or serologically positive patients. VL with unusual signs and symptoms may develop in immunocompromised patients with previous LST positivity after immunosuppressive treatments. Information about LST positivity is useful for calling attention to this potential risk for VL that may have unusual manifestations in these persons.

Antonio Cascio and Chiara Iaria
Author affiliations: University of Messina, Messina, Italy (A. Cascio); and Sapienza University of Rome, Rome, Italy (C. Iaria)

Suggested citation for this article:
Cascio A, Iaria C. Appropriate screening for leishmaniasis before immunosuppressive treatments [letter]. Emerg Infect Dis. 2009 Oct [date cited]. Available from http://www.cdc.gov/EID/content/15/10/1705.htm#cascio

DOI: 10.3201/eid1510.090881

References
Xynos ID, Tektonidou MG, Pikazis D, Sipsas NV. Leishmaniasis, autoimmune rheumatic disease, and anti–tumor necrosis factor therapy, Europe. Emerg Infect Dis. 2009;15:956–9. PubMed DOI
Barao SC, de Fonseca Camargo-Neves VL, Resende MR, da Silva LJ. Human asymptomatic infection in visceral leishmaniasis: a seroprevalence study in an urban area of low endemicity. Preliminary results. Am J Trop Med Hyg. 2007;77:1051–3.
Braz RF, Nascimento ET, Martins DR, Wilson ME, Pearson RD, Reed SG, et al. The sensitivity and specificity of Leishmania chagasi recombinant K39 antigen in the diagnosis of American visceral leishmaniasis and in differentiating active from subclinical infection. Am J Trop Med Hyg. 2002;67:344–8.
Badero R, Jones TC, Carvalho EM, Sampaio D, Reed SG, Barral A, et al. New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis. 1986;154:1003–11.
Hailu A, Berhe N, Sisay Z, Abraham I, Medhin G. Seroepidemiological and leishmanin skin test surveys of visceral leishmaniasis in south and southwest Ethiopia. Ethiop Med J. 1996;34:11–23.
Back to top


--------------------------------------------------------------------------------

In Response: In their letter responding to our recently published article (1) Cascio and Iaria spark an important discussion on the usefulness of screening for Leishmania infection before administering biologic agents or other immunosuppressive treatments to patients having autoimmune rheumatic diseases and living in areas where Leishmania parasites are endemic (2). Although we agree in principle that early detection of asymptomatic Leishmania infection will decrease the incidence of the disease in immunosuppressed patients, current diagnostic tools may have a limited (or restricted) role in detecting Leishmania infection in this vulnerable patient population. Screening for leishmaniasis has been hampered by the lack of a standard test. Currently available serologic methods have variable sensitivities, specificities, and cross-reactivities, depending on the species being tested and the region where tests are performed. Many experts believe that serologic tests may complement other existing diagnostic tools, raising cost-efficiency concerns, especially in financially deprived countries (3).

A positive leishmanin skin test (LST) result indicates exposure to Leishmania spp. and is generally thought to reflect a durable cell-mediated immune response. No cross-reaction occurs in patients with Chagas disease, but some cross-reactions are found in patients with glandular tuberculosis or lepromatous leprosy (4). Sustained positive responses have been documented for up to 20 years after exposure to the Leishmania parasite. Nevertheless, LST has limitations. In a longitudinal study of visceral leishmaniasis in Bangladesh, Bern et al. reported loss of LST sensitivity attributed to antigen-production issues, such as standardization and documentation of sensitivity, potency, and stability of leishmanin antigens (5). Also, prior treatment with immunosuppressive agents, which influence cell-mediated immunity, may decrease LST prognostic potency similarly to changes observed for the tuberculin skin test in similar settings (6).

Variations in specificities and sensitivities limit the diagnostic potential of available diagnostic tools. The context of immunosuppression further contributes to the diagnostic complications and increases the need for additional research in leishmaniasis diagnostics.

Ioannis D. Xynos, Maria G. Tektonidou, Dimitrios Pikazis, and Nikolaos V. Sipsas
Author affiliations: National and Kapodistrian University of Athens, Athens, Greece (I.D. Xynos, D. Pikazis, N.V. Sipsas); and Euroclinic Hospital of Athens, Athens (M.G. Tektonidou)

Suggested citation for this article:
Xynos ID, Tektonidou M, Pikazis D, Sipsas NV. Appropriate screening for leishmaniasis before immunosuppressive treatments [response]. Emerg Infect Dis. 2009 Oct [date cited]. Available from http://www.cdc.gov/EID/content/15/10/1706.htm#xynos

DOI: 10.3201/eid1510.091024

References
Xynos ID, Tektonidou MG, Pikazis D, Sipsas NV. Leishmaniasis, autoimmune rheumatic disease, and anti–tumor necrosis factor therapy, Europe. Emerg Infect Dis. 2009;15:956–9. PubMed DOI
Cascio A, Iaria C. Appropriate screening for leishmaniasis before immunosuppressive treatments. Emerg Infect Dis. 2009;15:1705–6.
Zijlstra EE, Nur Y, Desjeux P, Khalil EA, El-Hassan AM, Groen J. Diagnosing visceral leishmaniasis with the recombinant K39 strip test: experience from the Sudan. Trop Med Int Health. 2001;6:108–13. PubMed DOI
Singh S, Sivakumar R. Recent advances in the diagnosis of leishmaniasis. J Postgrad Med. 2003;49:55–60. PubMed DOI
Bern C, Amann J, Haque R, Chowdhury R, Ali M, Kurkjian KM, et al. Loss of leishmanin skin test antigen sensitivity and potency in a longitudinal study of visceral leishmaniasis in Bangladesh. Am J Trop Med Hyg. 2006;75:744–8.
Lalvani A, Millington KA. Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmun Rev. 2008;8:147–52. PubMed DOI

abrir aquí para acceder al documento CDC original:
Appropriate Screening for Leishmaniasis before Immunosuppressive Treatments | CDC EID